$BLRX bottom. Pr. $2.02 BioLineRx Reports First
Post# of 82
Posted On: 05/20/2014 8:05:27 AM
$BLRX bottom. Pr. $2.02
BioLineRx Reports First Quarter 2014 Financial Results
Company Poised to Execute on Multiple Clinical Milestones
news release
Consensus
20-F/A 5/15/14
O/S shares 241,487,049
Website
recent trades
Stockwatch
Buy Opinion (composite)
Nasdaq
BioLineRx Reports First Quarter 2014 Financial Results
5/20/2014 7:00:00 AM - Business Wire
BioLineRx to Report First Quarter 2014 Results on May 20, 2014
5/15/2014 7:00:00 AM - Business Wire
Update on BioLineRx's BL-8040 - Analyst Blog
4/11/2014 6:10:01 PM - Zacks.com
BioLineRx Announces Investigator-Initiated Study for Novel
Chronic Myeloid Leukemia Treatment
4/10/2014 7:00:00 AM - Business Wire
Israeli Biomed-Tech Companies Present Investment Opportunities
4/9/2014 9:10:00 AM - Seeking Alpha
BioLineRx Reports First Quarter 2014 Financial Results
Company Poised to Execute on Multiple Clinical Milestones
news release
Consensus
20-F/A 5/15/14
O/S shares 241,487,049
Website
recent trades
Stockwatch
Buy Opinion (composite)
Nasdaq
BioLineRx Reports First Quarter 2014 Financial Results
5/20/2014 7:00:00 AM - Business Wire
BioLineRx to Report First Quarter 2014 Results on May 20, 2014
5/15/2014 7:00:00 AM - Business Wire
Update on BioLineRx's BL-8040 - Analyst Blog
4/11/2014 6:10:01 PM - Zacks.com
BioLineRx Announces Investigator-Initiated Study for Novel
Chronic Myeloid Leukemia Treatment
4/10/2014 7:00:00 AM - Business Wire
Israeli Biomed-Tech Companies Present Investment Opportunities
4/9/2014 9:10:00 AM - Seeking Alpha
(0)
(0)